Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Several Midwestern Cities have been designated as HIV “hotspots” due to the rising number of new cases; and the South ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

Rep. Marjorie Taylor Greene (R-GA) ranted about how the U.S. sends money to Africa to prevent the spread of HIV, arguing that ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...